🇺🇸 Infanrix-IPV/Hib in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Jaundice — 2 reports (15.38%)
  2. Pneumonia — 2 reports (15.38%)
  3. Pyrexia — 2 reports (15.38%)
  4. Acute Sinusitis — 1 report (7.69%)
  5. Adverse Event Following Immunisation — 1 report (7.69%)
  6. Anaemia — 1 report (7.69%)
  7. Attention Deficit Hyperactivity Disorder — 1 report (7.69%)
  8. Body Temperature Increased — 1 report (7.69%)
  9. Conjunctivitis — 1 report (7.69%)
  10. Crying — 1 report (7.69%)

Source database →

Other Immunology approved in United States

Frequently asked questions

Is Infanrix-IPV/Hib approved in United States?

Infanrix-IPV/Hib does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Infanrix-IPV/Hib in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.